Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03856047 · ClinicalTrials.gov registry record · Phase 2
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 706
- Enrollment target
NCT03856047: Completed Phase 2 study, sponsored by Novo Nordisk A/S.
NCT03856047 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 706 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (431% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03856047, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 706 participants
- Enrollment target
Study Summary
This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study. As well as taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. Participants will either take NNC0174-0833, liraglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take one injection once a week or once a day, depending on the treatment. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 8 months. Participants will have 12 clinic visits with the study doctor.
Primary Outcome
Change in body weight (%) from week 0 to week 26 is presented. For descriptive analysis and statistical analysis the endpoint was evaluated based on the data from in-trial period and treatment adherent period, respectively. In-trial period was defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. Follow-up time for positive antibodies was not included in the in-trial period. Treatment-adherent: a participant is treatment adherent until the
Interventions
- DRUG NNC0174-0833
- DRUG Liraglutide 3.0 mg
- DRUG Placebo (NNC0174-0833)
- DRUG Placebo (Liraglutide 3.0 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 706 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2021-03-25 |
| Phase | Phase 2 |
What the finished NCT03856047 record still lists
NCT03856047 is an interventional study that assigns participants to a tested intervention. The registered 706 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (431% higher).
The record links to 0 conditions, and to 4 interventions - of which NNC0174-0833 is the first listed.
NCT03856047 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03856047 about?
NCT03856047 is a clinical study titled "Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.". This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study. As well as taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and wh...
What is the current status of trial NCT03856047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 706 participants. The study started on 2019-03-01. Estimated completion is 2021-03-25.
What interventions are being tested in trial NCT03856047?
The interventions under investigation include: NNC0174-0833 (DRUG), Liraglutide 3.0 mg (DRUG), Placebo (NNC0174-0833) (DRUG), Placebo (Liraglutide 3.0 mg) (DRUG).
Who is sponsoring clinical trial NCT03856047?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03856047's enrollment target sits among peer trials
706 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI